The Foster City, California-based biopharmaceutical company Gilead Sciences shares showed a drop of more than 10% after weak mid-stage data on an experimental hepatitis C drug it gained from its $11 billion acquisition of Pharmasset. The drop in stock appeared following the company released a nucleotide analogue polymerase inhibitor GS-7977, Phase II study data.

The company said mostly HCV genotype 1 patients, who had a prior ‘null’ response to an interferon-containing regimen, showed a viral relapse within four weeks after accomplishing 12 weeks treatment plan. Data for eight patients out of 10 participants in this case of the trial and among those eight there appeared six who had a viral relapse.

Gilead lost the most among biotechnology stocks holding over 1M volume on Friday, with mostly in negative territory including Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Vical Incorporated (NASDAQ:VICL) and Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) all fell more than 4% while BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Illumina, Inc. (NASDAQ:ILMN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), YM BioSciences Inc. (USA) (NYSEAMEX:YMI), BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and InterMune, Inc.(NASDAQ:ITMN) lost between 3% and 3.99%.

On the strong side, Sangamo Biosciences, Inc. (NASDAQ:SGMO) gained the most with 26.90%, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) soared 26.17%, Cell Therapeutics, Inc. (NASDAQ:CTIC) jumped 21.62% and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 13%.

Shares price of Gilead Sciences, Inc.(NASDAQ:GILD) started the last session with $46.00 and during the session hit a peak price of $47.88 then closed the trade showing a loss of 14.25% to settle at $47.00.

While taking into consideration its trading capacity, last trade volume of 62.50 million shares was above from average volume of 10.29 million shares.

The company’s week performance moved at -12.56%, 1 year performance remained at +19.62%, and year-to-date performance appeared positive with +14.83% while a month-performance after last trade close went down at -0.44%.

GILD generated revenue of $8.39 billion in the following twelve months and earned $2.80 billion. The Company showed a positive +33.26% in the net profit margin and its operating margin which remained +45.20%. Company’s annual sales growth for the past five years was +24.60%.

The volatility in stock price was 2.32% for a week and 2.01% for a month as well as price volatility’s Average True Range for 14 days was 1.74 and its beta remained 0.49.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.